A recent report suggested that JAK2 signaling might occur in ET megakaryocytes with CALR mutations; however, the downstream signaling mechanisms other than those involving STAT3 and STAT5 are likely involved in the pathogenesis of MPN with CALR mutations (Lau et al. 2015). This evidence concerns the gene JAK2 and myeloproliferative neoplasm.